We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Danaher and Johns Hopkins University Collaborate to Improve Neurological Diagnosis

By LabMedica International staff writers
Posted on 13 May 2024
Print article
Image: Scientists will evaluate new blood-based biomarkers using highly sensitive technology (Photo courtesy of 123RF)
Image: Scientists will evaluate new blood-based biomarkers using highly sensitive technology (Photo courtesy of 123RF)

Unlike severe traumatic brain injury (TBI), mild TBI often does not show clear correlations with abnormalities detected through head computed tomography (CT) scans. Consequently, there is a pressing need for a more reliable method to determine which patients should receive a CT scan and to identify those at greater risk of developing severe symptoms. Now, a new collaboration that aims to identify mild TBI earlier could help nearly 56 million patients worldwide with mild TBI benefit from a more accurate approach to diagnosis.

Danaher Corporation (Washington, D.C., USA) has entered into a collaboration with Johns Hopkins University (Baltimore, MD, USA) to develop new diagnostic methods for mild TBI. This collaboration is part of the Danaher Beacons program, where Johns Hopkins researchers will utilize technology from Beckman Coulter Diagnostics, a subsidiary of Danaher, to establish correlations between between novel biomarker panels and clinical outcomes. The Beacon builds on recent advancements in neurological biomarker research and the application of next-generation immunoassay detection technologies developed by Beckman Coulter. Should this method prove successful, it could also be adapted to diagnose other forms of brain injuries and neurodegenerative diseases.

"Our latest in vitro diagnostics innovations are improving the detection of specific biomarkers found in blood when brain cells are damaged,” said Julie Sawyer Montgomery, Vice President and Group Executive, Danaher Diagnostics. “We are thrilled to partner with Johns Hopkins with the goal of leveraging these solutions to develop tests for earlier and more precise diagnosis of mild TBI, which could ultimately lead to improved treatment outcomes and faster recovery for patients."


Print article

Channels

Clinical Chemistry

view channel
Image: The new ADLM guidance will help healthcare professionals navigate respiratory virus testing in a post-COVID world (Photo courtesy of 123RF)

New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections

Respiratory tract infections, predominantly caused by viral pathogens, are a common reason for healthcare visits. Accurate and swift diagnosis of these infections is essential for optimal patient management.... Read more

Molecular Diagnostics

view channel
Image: The blood test uses AI to predict Parkinson’s seven years before onset of symptoms (Photo courtesy of Kateryna Kon/Shutterstock)

AI-Powered Blood Test Predicts Parkinson's Seven Years before Symptoms Appear

Parkinson’s disease is currently the fastest-growing neurodegenerative disorder worldwide, affecting nearly 10 million people globally. It is a progressive disease caused by the deterioration and death... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.